Carna Biosciences Inc. and Sumitomo Pharma Co. Ltd. have identified dual-specificity tyrosine-(Y)-phosphorylation regulated kinase (DYRK) inhibitors reported to be useful for the treatment of cancer, depression, epilepsy, dementia, psychosis, thyroid and gastrointestinal disorders, among others.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has divulged protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
Hangzhou Healzen Therapeutics Co. Ltd. has synthesized programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of cancer, infections, immunological and inflammatory disorders.
Researchers at Cincinnati Children's Hospital Medical Center, Kurome Therapeutics Inc. and the U.S. Department of Health and Human Services have disclosed IL-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.
Nuclear body protein SP140 is mainly expressed on immune cells such as B and T cells, monocytes or dendritic cells and they are activated by interferon and regulated upon cellular stress, such as during viral infections.
Microglial cells (MGs) are resident immune cells in the brain, which play a key role in the acute response and chronic recovery to stroke. Investigators at the University of Texas Health Science Center Houston aimed to evaluate MG transcriptomic response to stroke in mouse brain.
Medulloblastomas (MBs) are the most common malignant brain tumors in pediatric patients. Among the different types of MBs, those driven by MYC amplification present the worst prognosis. In a recent study published in Nature Communications, scientists from Cincinnati Children's Hospital Medical Center and collaborators investigated the molecular and genetic events triggering MYC amplification and malignant transformation in MBs, which remained previously unclear.
RSS
